Back to results
US 2022/0010274 A1Published application
Personalized neoantigen-specific adoptive cell therapies
AssigneePact Pharma, Inc.
InventorsBarbara Sennino, Kyle Jacoby, Susan Foy, Ines Mende, Stefanie Mandl-Cashman
Life of this patent
Estimating the term…
Abstract
Methods of genetically engineering NeoTCR Products comprising young T cells and methods of manufacturing such cell products.
Claims20
A method of producing a population of modified young T cells, comprising:
- a) introducing via electroporation into a T cell a homologous recombination (HR) template nucleic acid sequence comprising:
- i. first and second homology arms homologous to first and second target nucleic acid sequences;
- ii. a T cell receptor (TCR) gene sequence positioned between the first and second homology arms;
- b) recombining the HR template nucleic acid into an endogenous TCR gene locus;
- and
- c) culturing the T cell in the presence of interleukin 2 (IL2), interleukin 7 (IL7), interleukin 15 (IL15), or any combination thereof, to thereby produce a population of modified young T cells.
3 more elements
Dependencies are inferred from the claim text.